

2018 Educational Session Content References

General Session I: Oral Cavity

How Better Radiation (and Support) Can Impact Quality of Life

1. Ringash, J., Bernstein, L. J., Devins, G., Dunphy, C., Giuliani, M., Martino, R., & McEwen, S. (2018). Head and neck cancer survivorship: Learning the needs, meeting the needs. *Seminars in Radiation Oncology*, 28(1), 64-74.
2. Ringash, J. (2017). Quality of life in head and neck cancer: Where we are, and where we are going. *International Journal of Radiation Oncology • Biology • Physics*, 97(4), 662-666.

Pre-operative Therapy and Chemoprevention

1. Monteiro de Oliveira Novaes, J. A., & William Jr, W. N. (2016). Prognostic factors, predictive markers and cancer biology: The triad for successful oral cancer chemoprevention. *Future Oncology*, 12(19), 2379-2386.

General Session II: Tonsil and Base of Tongue

Dose/Volume De-escalation Protocols

1. Caudell, J. J., Torres-Roca, J. F., Gillies, R. J., Enderling, H., Kim, S., Rishi, A., ... & Harrison, L. B. (2017). The future of personalised radiotherapy for head and neck cancer. *The Lancet Oncology*, 18(5), e266-e273.
2. Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., ... & Kim, H. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. *New England Journal of Medicine*, 363(1), 24-35.
3. Sher, D. J., Adelstein, D. J., Bajaj, G. K., Brizel, D. M., Cohen, E. E., Halthore, A., ... & Rocco, J. W. (2017). Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO evidence-based clinical Practice guideline. *Practical Radiation Oncology*, 7(4), 246-253.

Does Chemoselection Have a Role in Oropharynx Cancer?

1. Marur, S., Li, S., Cmelak, A. J., Gillison, M. L., Zhao, W. J., Ferris, R. L., ... & Trevarthen, D. R. (2016). E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx—ECOG-ACRIN cancer research group. *Journal of Clinical Oncology*, 35(5), 490-497.
2. Cmelak, A., Li, S., Marur, S., Zhao, W., Westra, W. H., Chung, C. H., ... & Ferris, R. L. (2015). Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNS V2). *Journal of Clinical Oncology*, 33(15_suppl), 6021.

Minimally Invasive Procedures

1. Weinstein, G. S., O'Malley, B. W., Snyder, W., Sherman, E., & Quon, H. (2007). Transoral robotic surgery: Radical tonsillectomy. *Archives of Otolaryngology—Head & Neck Surgery*, 133(12), 1220-1226.
2. Iseli, T. A., Kulbersh, B. D., Iseli, C. E., Carroll, W. R., Rosenthal, E. L., & Magnuson, J. S. (2009). Functional outcomes after transoral robotic surgery for head and neck cancer. *JAMA Otolaryngology—Head and Neck Surgery*, 141(2), 166-171.
3. Weinstein, G. S., O'Malley, B. W., Magnuson, J. S., Carroll, W. R., Olsen, K. D., Daio, L., ... & Holsinger, F. C. (2012). Transoral robotic surgery: A multicenter study to assess feasibility, safety, and surgical margins. *The Laryngoscope*, 122(8), 1701-1707.

Co-sponsors:



General Session III: Nasopharynx

1. Sun, Y., Li, W. F., Chen, N. Y., Zhang, N., Hu, G. Q., Xie, F. Y., ... & Hu, C. S. (2016). Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. *The Lancet Oncology*, 17(11), 1509-1520.
2. Al-Sarraf, M., LeBlanc, M., Giri, P. G., Fu, K. K., Cooper, J., Vuong, T., ... & Ensley, J. F. (1998). Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. *Journal of Clinical Oncology*, 16(4), 1310-1317.

Tumor Board: Early Stage Disease

1. Sher, D. J., Adelstein, D. J., Bajaj, G. K., Brizel, D. M., Cohen, E. E., Halthore, A., ... & Rocco, J. W. (2017). Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO evidence-based clinical practice guideline. *Practical Radiation Oncology*, 7(4), 246-253.
2. Holsinger, F. C., & Ferris, R. L. (2015). Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: Robotics, lasers, and clinical trials. *Journal of Clinical Oncology*, 33(29), 3285-3292.
3. D’Cruz, A. K., Vaish, R., Kapre, N., Dandekar, M., Gupta, S., Hawaldar, R., ... & Kane, S. (2015). Elective versus therapeutic neck dissection in node-negative oral cancer. *New England Journal of Medicine*, 373(6), 521-529.
4. Ganly, I., Goldstein, D., Patel, S., Lee, N., Gullane, P., & Shah, J. (2011). Long term regional control and survival in patients with “low risk” early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: The importance of depth of invasion. *International Journal of Radiation Oncology • Biology • Physics*, 81(2), S105-S106.
5. Forastiere, A. A., Ismaila, N., Lewin, J. S., Nathan, C. A., Adelstein, D. J., Eisbruch, A., ... & O’Malley, B. (2017). Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. *Journal of Clinical Oncology*, doi: 10.1200/JCO.2017.75.7385.
6. Zanon, D. K., Migliacci, J. C., Xu, B., Katabi, N., Montero, P. H., Ganly, I., ... & Patel, S. G. (2017). A Proposal to redefine close surgical margins in squamous cell carcinoma of the oral tongue. *JAMA Otolaryngology–Head & Neck Surgery*, 143(6), 555-560.

General Session IV: Larynx

Preserving the Functional Larynx for Locally Advanced Larynx Cancer

1. Forastiere, A. A., Zhang, Q., Weber, R. S., Maor, M. H., Goepfert, H., Pajak, T. F., ... & Thorstad, W. (2012). Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *Journal of Clinical Oncology*, 31(7), 845-852.
2. Janoray, G., Pointreau, Y., Garaud, P., Chapet, S., Alfonsi, M., Sire, C., ... & Calais, G. (2015). Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ±docetaxel for larynx preservation. *Journal of the National Cancer Institute*, 108(4), djv368.
3. Lefebvre, J. L., Pointreau, Y., Rolland, F., Alfonsi, M., Baudoux, A., Sire, C., ... & Blot, E. (2013). Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPIN randomized phase II study. *Journal of Clinical Oncology*, 31(7), 853-859.

Systemic Therapy for Larynx Cancer

Co-sponsors:



1. Wolf, G. T., Bellile, E., Eisbruch, A., Urba, S., Bradford, C. R., Peterson, L., ... & McLean, S. A. (2017). Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer. *JAMA Otolaryngology–Head & Neck Surgery*, 143(4), 355-366.
2. Gorphe, P., Matias, M., Blanchard, P., Even, C., Ferte, C., Tao, Y., ... & Janot, F. (2017). Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy. *The Laryngoscope*, 127(8), 1791-1796.
3. Janoray, G., Pointreau, Y., Garaud, P., Chapet, S., Alfonsi, M., Sire, C., ... & Calais, G. (2015). Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ±docetaxel for larynx preservation. *Journal of the National Cancer Institute*, 108(4), djv368.
4. Ramakodi, M. P., Devarajan, K., Blackman, E., Gibbs, D., Luce, D., Deloumeaux, J., ... & Ragin, C. C. (2017). Integrative genomic analysis identifies ancestry-related expression quantitative trait loci on DNA polymerase β and supports the association of genetic ancestry with survival disparities in head and neck squamous cell carcinoma. *Cancer*, 123(5), 849-860.

General Session V: Salivary Glands and Thyroid

1. Seethala, R. R., & Griffith, C. C. (2016). Molecular pathology: Predictive, prognostic, and diagnostic markers in salivary gland tumors. *Surgical Pathology Clinics*, 9(3), 339-352.
2. Xu, B., & Ghossein, R. (2017). Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management. *European Journal of Surgical Oncology: The Journal of Cancer Surgery*. doi:10.1016/j.ejso.2017.05.002

Breakout Session I: Early Research and Models

Radiomics and Mathematical Models

1. Caudell, J. J., Torres-Roca, J. F., Gillies, R. J., Enderling, H., Kim, S., Rishi, A., ... & Harrison, L. B. (2017). The future of personalised radiotherapy for head and neck cancer. *The Lancet Oncology*, 18(5), e266-e273.
2. Prokopiou, S., Moros, E. G., Poleszczuk, J., Caudell, J., Torres-Roca, J. F., Latifi, K., ... & Enderling, H. (2015). A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation. *Radiation Oncology*, 10(1), 159.

Immune Targeting in Head and Neck Squamous Cell Carcinoma: PD-L1, Vaccines and Beyond

1. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., ... & Lennon, V. A. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. *Nature Medicine*, 8(8), 793.
2. Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., ... & Kasperbauer, J. L. (2003). B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. *Cancer Research*, 63(19), 6501-6505.
3. Pai, S. I., Zandberg, D. P., & Strome, S. E. (2016). The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment. *Oral Oncology*, 61, 152-158.

Humanized Laboratory Models to Study the Tumor-stroma Interaction and Translate Immune-directed Therapies

1. Morton, J. J., Bird, G., Refaeli, Y., & Jimeno, A. (2016). Humanized mouse xenograft models: Narrowing the tumor–microenvironment Gap. *Cancer Research*, 76(21), 6153-6158.
2. Morton, J. J., Bird, G., Keysar, S. B., Astling, D. P., Lyons, T. R., Anderson, R. T., ... & Gan, G. (2016). XactMice: Humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. *Oncogene*, 35(3), 290.

Co-sponsors:



Breakout Session II: Survivorship and Acute and Late Effects

Oral Issues for the Radiotherapy Patient

1. Owosho, A. A., Tsai, C. J., Lee, R. S., Freymiller, H., Kadempour, A., Varthis, S., ... & Drill, E. (2017). The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience. *Oral Oncology*, 64, 44-51.
2. Owosho, A. A., Thor, M., Oh, J. H., Riaz, N., Tsai, C. J., Rosenberg, H., ... & Deasy, J. O. (2017). The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. *Journal of Cranio-Maxillo-Facial Surgery*, 45(4), 595-600.
3. Sulaiman, F., Hury, J. M., & Zlotolow, I. M. (2003). Dental extractions in the irradiated head and neck patient: A retrospective analysis of Memorial Sloan-Kettering Cancer Center protocols, criteria, and end results. *Journal of Oral and Maxillofacial surgery*, 61(10), 1123-1131.

Surveillance and Management of Late Effects of Head and Neck Cancer Therapy

1. Cohen, E. E., LaMonte, S. J., Erb, N. L., Beckman, K. L., Sadeghi, N., Hutcheson, K. A., ... & Lyman, G. H. (2016). American Cancer Society head and neck cancer survivorship care guideline. *CA: A Cancer Journal for Clinicians*, 66(3), 203-239.
2. Strojan, P., Hutcheson, K. A., Eisbruch, A., Beitler, J. J., Langendijk, J. A., Lee, A. W., ... & Ferlito, A. (2017). Treatment of late sequelae after radiotherapy for head and neck cancer. *Cancer Treatment Reviews*, 59, 79-92.
3. Hutcheson, K. A., Yuk, M., Hubbard, R., Gunn, G. B., Fuller, C. D., Lai, S. Y., ... & Kies, M. S. (2017). Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review. *Head & Neck*, 39(8), 1516-1523.

Tumor Board: Advanced Disease

1. Strojan, P., Corry, J., Eisbruch, A., Vermorken, J. B., Mendenhall, W. M., Lee, A. W., ... & Paleri, V. (2015). Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate. *Head & Neck*, 37(1), 134-150.
2. Sacco, A. G., & Cohen, E. E. (2015). Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. *Journal of Clinical Oncology*, 33(29), 3305-3313.
3. White, H., Ford, S., Bush, B., Holsinger, F. C., Moore, E., Ghanem, T., ... & Magnuson, J. S. (2013). Salvage surgery for recurrent cancers of the oropharynx: Comparing TORS with standard open surgical approaches. *JAMA Otolaryngology-Head & Neck Surgery*, 139(8), 773-777.
4. Beausang, E. S., Ang, E. E., Lipa, J. E., Irish, J. C., Brown, D. H., Gullane, P. J., & Neligan, P. C. (2003). Microvascular free tissue transfer in elderly patients: The Toronto experience. *Head & Neck*, 25(7), 549-553.
5. Szturz, P., & Vermorken, J. B. (2016). Treatment of elderly patients with squamous cell carcinoma of the head and neck. *Frontiers in Oncology*, 6, 199.
6. VanderWalde, N. A., Fleming, M., Weiss, J., & Chera, B. S. (2013). Treatment of older patients with head and neck cancer: A review. *The Oncologist*, 18(5), 568-578.

Co-sponsors:



General Session VI: Immunotherapy Advances in Head and Neck Cancer

Immunotherapy in Definitive Treatment in Combination with Radiotherapy (RT) and ChemoRT

1. Bauman, J. E., Cohen, E., Ferris, R. L., Adelstein, D. J., Brizel, D. M., Ridge, J. A., ... & Disis, M. L. (2017). Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee planning meeting. *Cancer*, 123(7), 1259-1271.
2. Sridharan, V., Margalit, D. N., Lynch, S. A., Severgnini, M., Zhou, J., Chau, N. G., ... & Haddad, R. I. (2016). Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. *British Journal of Cancer*, 115(2), 252.
3. Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015). Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. *The Lancet Oncology*, 16(13), e498-e509.

Keynote III: Melanoma of the Head and Neck

1. Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., ... & Kashani-Sabet, M. (2014). Final trial report of sentinel-node biopsy versus nodal observation in melanoma. *New England Journal of Medicine*, 370(7), 599-609.
2. Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., ... & Hoekstra, H. J. (2017). Completion dissection or observation for sentinel-node metastasis in melanoma. *New England Journal of Medicine*, 376(23), 2211-2222.
3. Schmalbach, C. E., & Bradford, C. R. (2015). Is sentinel lymph node biopsy the standard of care for cutaneous head and neck melanoma? *The Laryngoscope*, 125(1), 153-160.

Tumor Board: Rare Tumors and Non-Melanoma Skin Cancer of the Head and Neck

1. Jing, C., Gao, Z., Wang, R., Yang, Z., Shi, B., & Hou, P. (2017). Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. *American Journal of Cancer Research*, 7(4), 903.
2. Wang, X., Luo, Y., Li, M., Yan, H., Sun, M., & Fan, T. (2017). Management of salivary gland carcinomas-a review. *Oncotarget*, 8(3), 3946.
3. Jethanamest, D., Morris, L. G., Sikora, A. G., & Kutler, D. I. (2007). Esthesioneuroblastoma: A population-based analysis of survival and prognostic factors. *Archives of Otolaryngology—Head & Neck Surgery*, 133(3), 276-280.
4. Han, A., & Ratner, D. (2007). What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? *Cancer*, 109(6), 1053-1059.
5. McLean, J. N., Nunley, S. R., Klass, C., Moore, C., Susan, M., & Peter, A. J. (2007). Combined modality therapy of esthesioneuroblastoma. *Otolaryngology—Head and Neck Surgery*, 136(6), 998-1002.

Co-sponsors:

